Rahlfs Capital’s AbbVie ABBV Stock Holding History

Rahlfs Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.39M	Sell	6,399 -550	-8%	-$122K	1.02%	32
2025 Q4	$1.59M	Sell	6,949 -63	-0.9%	-$14.4K	1.23%	25
2025 Q3	$1.62M	Hold	7,012	–	–	1.28%	23
2025 Q2	$1.3M	Sell	7,012 -500	-7%	-$92.9K	1.19%	25
2025 Q1	$1.57M	Hold	7,512	–	–	1.58%	19
2024 Q4	$1.33M	Buy	+7,512	New	+$1.38M	1.32%	21

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rahlfs Capital's ABBV Position: Q1 2026 in Review

Rahlfs Capital reduced its AbbVie (ABBV) stake by 7.9% in Q1 2026, selling an estimated $122K and leaving 6,399 shares worth $1.39M. The position accounts for 1.02% of the portfolio, ranked #32.

Rahlfs Capital first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.62M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Rahlfs Capital held 6,399 shares of AbbVie worth $1.39M as of Q1 2026.
Rahlfs Capital sold 550 AbbVie shares in Q1 2026, an estimated $122K.
AbbVie made up 1.02% of Rahlfs Capital's portfolio in Q1 2026, its #32 holding.
Rahlfs Capital first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
Rahlfs Capital's AbbVie position peaked at $1.62M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Rahlfs Capital's 13F filing for Q1 2026, filed 11 May 2026.